Trials / Completed
CompletedNCT00731250
A Study To Assess The Effect Of SB-705498 In A Capsaicin Challenge Model
A Randomised, Double-blind, Placebo-controlled Study to Assess the Effect of Oral, Single Dose SB-705498 in a Validated Intranasal Capsaicin Challenge Model in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 45 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
This study is designed to look at the affect of SB-705498 on rhinitis symptoms, as induced by capsaicin challenge
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SB-705498 | Subjects will be administered a single dose of 400 mg SB-705498 |
| DRUG | Placebo | Subjects will be administered SB-705498 matching placebo tablets |
| OTHER | Caspaicin | Subjects will be challenged with 0.5 µg, 5.0 µg and 50 µg intranasal dose |
Timeline
- Start date
- 2008-07-22
- Primary completion
- 2009-03-01
- Completion
- 2009-03-31
- First posted
- 2008-08-08
- Last updated
- 2017-07-13
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT00731250. Inclusion in this directory is not an endorsement.